CANY
SAGE

Caxton Associates (New York)’s Sage Therapeutics SAGE Stock Holding History

Caxton Associates (New York)’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-55,745
Closed -$1.04M – 583
2024
Q1 		$1.04M Sell
55,745
-64,036
-53% -$1.48M 0.06% 213
2023
Q4 		$2.6M Buy
119,781
+51,746
+76% +$1.03M 0.13% 93
2023
Q3 		$1.4M Buy
+68,035
New +$1.96M 0.19% 98
2022
Q3 		– Sell
-18,426
Closed -$595K – 646
2022
Q2 		$595K Buy
+18,426
New +$618K 0.06% 230
2022
Q1 		– Sell
-17,550
Closed -$747K – 675
2021
Q4 		$747K Buy
17,550
+6,190
+54% +$259K 0.08% 175
2021
Q3 		$503K Buy
+11,360
New +$521K 0.06% 202

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Caxton Associates (New York)'s SAGE Position: Q2 2024 in Review

Caxton Associates (New York) sold out of Sage Therapeutics (SAGE) in Q2 2024, closing a stake of 55,745 shares — an estimated $1.04M sold.

Caxton Associates (New York) first reported a position in SAGE in Q3 2021 and held it in 6 quarters. The position peaked at $2.6M in Q4 2023. 195 funds tracked by Wall St. Rank hold SAGE as of Q2 2024.

  • Caxton Associates (New York) reported no remaining Sage Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 55,745 Sage Therapeutics shares in Q2 2024, an estimated $1.04M.
  • Caxton Associates (New York) first reported a position in Sage Therapeutics in Q3 2021 and held it in 6 quarters.
  • Caxton Associates (New York)'s Sage Therapeutics position peaked at $2.6M in Q4 2023.
  • 195 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2024.

Based on Caxton Associates (New York)'s 13F filing for Q2 2024, filed 14 Aug 2024.